Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Investors fled the company's stock in 2024 as a slow US launch of Leqembi, the Alzheimer's disease drug it sells with Japan's ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than in the US.

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

We currently have no ESAIY Stock Split History on this stock.